{"entity":{"id":"orm-1153","kind":"drug","name":"ORM-1153","aka":[],"tldr":"ORM-1153 is an experimental degrader-antibody conjugate from Orum Therapeutics, in phase 1 trials for CD123-positive acute myeloid leukaemia.","summary":"ORM-1153 is a degrader-antibody conjugate from Orum Therapeutics. An anti-CD123 antibody joined by a cleavable beta-glucuronide linker to a GSPT1-degrading payload; once inside the cell it releases the payload, which kills the cancer cell by degrading GSPT1. Its furthest stage is phase 1, for CD123-positive acute myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07809906 recruiting; first patient dosed per company release of 14 October 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Orum Therapeutics: orumrx.com","url":"https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in"},{"label":"Orum Therapeutics: orumrx.com","url":"https://www.orumrx.com/news/orum-therapeutics-doses-fir-phase-1-trial-of-orm-1153-a-cd123-gspt1-degrader-antibody-conjugatest-patient-in"},{"label":"Orum Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07809906"},{"label":"ClinicalTrials.gov: trials of ORM-1153","url":"https://clinicaltrials.gov/search?intr=ORM-1153"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["cd123"],"drugs":[],"companies":["orum-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07809906"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ORM-1153","modality":"Degrader-antibody conjugate","mechanism":"An anti-CD123 antibody joined by a cleavable beta-glucuronide linker to a GSPT1-degrading payload; once inside the cell it releases the payload, which kills the cancer cell by degrading GSPT1.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/orm-1153/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/"}],"company":[{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/"}],"trial":[{"id":"nct07809906","kind":"trial","name":"Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression","route":"/trials/nct07809906/"}]}}